Detection of hemagglutinin using Affinité’s P4SPRTM as a potential platform to monitor production of influenza vaccine
The influenza vaccine is manufactured each year to protect people against serious illness that require hospitalization and reduce the number of mortalities associated with influenza. Therefore, the timely production and validation of influenza vaccine lots are of utmost importance. Each vaccine lot must be evaluated for potency, which is based on the amount of the hemagglutinin (HA) content found on influenza viruses in the vaccine.
